By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celyad (Formally Known as Cardio3 BioSciences) 

Parc de L’Alliance
9, Boulevard de France
Braine - L’Alleud    1420  Belgium
Phone: 32-2-790-35-30 Fax: 32-2-790-35-35



Company News
Celyad Publishes Additional Pre-Clinical Data In Support Of THINK Trial 6/21/2017 8:24:29 AM
Celyad Reports Promising Early Results At First Dose Level Of The Solid Arm Of The THINK Trial 6/19/2017 10:49:51 AM
Celyad Obtains Additional US Patent For Cancer Treatment Based On TCR-Deficient Allogeneic CAR-T Cells 5/30/2017 9:59:51 AM
Celyad Announces First Quarter 2017 Business Update 5/19/2017 11:34:19 AM
Celyad Announces First Quarter 2017 Business Update 5/19/2017 8:02:50 AM
FDA Grants Fast Track Designation For Celyad’s Ischemic Heart Failure Therapy, C-Cure 5/11/2017 11:56:02 AM
Celyad Grants To Novartis AG (NVS) A Non-Exclusive License For Its Allogeneic TCR-Deficient CAR-T Cells Patents 5/2/2017 11:00:22 AM
Celyad Reports 2016 Financial And Operating Results And Expected Key Milestones For 2017 3/23/2017 10:13:25 AM
USPTO Rejects New Reexamination Request Against Celyad’s US Patent For Production Of Allogeneic TCR-Deficient CAR-T Cells 3/16/2017 7:46:03 AM
Celyad Obtains FDA Approval To Initiate The NKR-2 CAR T Cells THINK Trial In The U.S. 3/8/2017 10:23:16 AM